IBS-D Drug Launched as Two-Week Treatment Pack

IBS-D Drug Launched as Two-Week Treatment Pack
IBS-D Drug Launched as Two-Week Treatment Pack

Salix announced the availability of Xifaxan 550 in a new two-week treatment Pack. The Xifaxan two-week Pack contains 42 tablets, providing a full course of treatment for irritable bowel syndrome with diarrhea (IBS-D).

Xifaxan 550, a rifamycin antibiotic, is also indicated for the reduction in risk of overt hepatic encephalopathy occurrence. Rifaximin is a semi-synthetic derivative of rifampin and acts by binding to the beta subunit of bacterial DNA-dependent RNA polymerase blocking one of the steps in transcription. This results in inhibition of bacterial protein synthesis and consequently inhibits the growth of bacteria.

RELATED: Two Unique IBS-D Treatments Gain FDA Approval

Xifaxan 550 is already supplied in 60-count bottles and cartons.

For more information call (800) 508-0024 or visit Xifaxan.com.

Loading links....